Literature DB >> 35527321

Cancerization of ducts in hilar cholangiocarcinoma.

Jae W Lee1, Yang Zhang1, Tadashi Yoshizawa1,2, Pedram Argani1, Laura D Wood1,3, Kiyoko Oshima4.   

Abstract

Invasive cancers that arise from ductal structures can infiltrate and colonize pre-existing ducts in a process referred to as cancerization of ducts (COD). COD in cholangiocarcinoma is an under-studied process whose clinical significance remains poorly understood. Even though both cancerized ducts and biliary intraepithelial neoplasias (BilINs) show dysplastic changes, hallmarks of COD are (i) an abrupt transition from the normal/reactive epithelium to severe dysplasia and (ii) close proximity to invasive carcinoma with similar cytologic features. We investigated 113 cases of surgically resected hilar cholangiocarcinoma and identified COD in 37 cases (33%). Using immunohistochemistry, we found that COD and adjacent invasive carcinoma had a concordant pattern of p53 and SMAD4 staining in 95% (21/22) and 100% (21/21) of cases, respectively. In contrast, BilINs and cancerized ducts showed significantly lower levels of concordance in p53 and SMAD4 staining at 44% (8/18) and 47% (8/17) of cases, respectively (P = 0.0007 and 0.0001, respectively). By univariate analysis, positive lymph node metastasis (P = 0.027), positive final bile duct margin (P = 0.021), and the presence of COD (P = 0.020) were associated with decreased overall survival. We further performed multivariate analysis to demonstrate that positive lymph node metastasis (P = 0.031), positive final bile duct margin (P = 0.035), and COD (P = 0.0051) were correlated with decreased overall survival. Together, our study highlights that COD is a clinically significant process in hilar cholangiocarcinoma that can be identified using morphological criteria in conjunction with p53 and SMAD4 immunolabeling.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biliary intraepithelial neoplasia; Cancerization; Dysplasia; Hilar cholangiocarcinoma

Mesh:

Substances:

Year:  2022        PMID: 35527321      PMCID: PMC9379246          DOI: 10.1007/s00428-022-03333-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  33 in total

1.  Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.

Authors:  Yasuni Nakanuma; Yasunori Sato
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-21       Impact factor: 7.027

2.  Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.

Authors:  Andrea Ruzzenente; Matteo Fassan; Simone Conci; Michele Simbolo; Rita T Lawlor; Corrado Pedrazzani; Paola Capelli; Mirko D'Onofrio; Calogero Iacono; Aldo Scarpa; Alfredo Guglielmi
Journal:  Ann Surg Oncol       Date:  2015-12-30       Impact factor: 5.344

3.  Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.

Authors:  Yoh Zen; N Volkan Adsay; Krystof Bardadin; Romano Colombari; Linda Ferrell; Hironori Haga; Seung-Mo Hong; Prodromos Hytiroglou; Günter Klöppel; Gregory Y Lauwers; Dirk J van Leeuwen; Kenji Notohara; Kiyoko Oshima; Alberto Quaglia; Motoko Sasaki; Fausto Sessa; Arief Suriawinata; Wilson Tsui; Yutaka Atomi; Yasuni Nakanuma
Journal:  Mod Pathol       Date:  2007-04-13       Impact factor: 7.842

4.  Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma.

Authors:  Yasunori Sato; Kenichi Harada; Motoko Sasaki; Yasuni Nakanuma
Journal:  Virchows Arch       Date:  2013-02-28       Impact factor: 4.064

5.  KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.

Authors:  Maylee Hsu; Motoko Sasaki; Saya Igarashi; Yasunori Sato; Yasuni Nakanuma
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

6.  Extrahepatic bile duct carcinoma with extensive intraepithelial spread: a clinicopathological study of 21 cases.

Authors:  Yoshitsugu Nakanishi; Yoh Zen; Hiroshi Kawakami; Kanako Kubota; Tomoo Itoh; Satoshi Hirano; Eiichi Tanaka; Yasuni Nakanuma; Satoshi Kondo
Journal:  Mod Pathol       Date:  2008-04-18       Impact factor: 7.842

7.  Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.

Authors:  Yoshitsugu Nakanishi; Yoh Zen; Satoshi Kondo; Tomoo Itoh; Keita Itatsu; Yasuni Nakanuma
Journal:  Hum Pathol       Date:  2008-05-20       Impact factor: 3.466

Review 8.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

9.  Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.

Authors:  Chaitanya R Churi; Rachna Shroff; Ying Wang; Asif Rashid; HyunSeon C Kang; Jacqueline Weatherly; Mingxin Zuo; Ralph Zinner; David Hong; Funda Meric-Bernstam; Filip Janku; Christopher H Crane; Lopa Mishra; Jean-Nicholas Vauthey; Robert A Wolff; Gordon Mills; Milind Javle
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

Review 10.  The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.

Authors:  Dawn Q Chong; Andrew X Zhu
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.